Effect of Brij-78 on systemic delivery of insulin from an ocular device

Yung Chi Lee; Pahala Simamora; Samuel H. Yalkowsky

doi:10.1021/js960423s

Effect of Brij-78 on systemic delivery of insulin from an ocular device

Yung Chi Lee, Pahala Simamora, Samuel H. Yalkowsky

Pharmacology and Toxicology

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

An ocular insert is developed for the controlled systemic delivery of insulin. Commercially available Gelfoam absorbable gelatin sponge, USP, is used in the fabrication of the ocular insert in the form of a matrix system. Two eyedrop formulations and 13 eye device formulations were evaluated. The efficacy of insulin ocular delivery was quantitated by monitoring the changes in its pharmacological response (i.e., blood glucose lowering). The in vivo results from devices containing 0.5 or 1.0 mg of insulin with 20 μg of p.- 2. ether (Brij-78) give a substantial improvement in insulin activity and a significant prolongation in its duration compared with the eyedrops. In addition, the mean blood glucose concentration returns to nearly normal levels within 60 rain after the removal of the device. Overall, the application of the Gelfoam device makes it feasible to obtain a prolonged systemic delivery of insulin within the desired therapeutic levels without the risk of hypoglycemia.

Original language	English (US)
Pages (from-to)	430-433
Number of pages	4
Journal	Journal of pharmaceutical sciences
Volume	86
Issue number	4
DOIs	https://doi.org/10.1021/js960423s
State	Published - Apr 1997

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.1021/js960423s

Cite this

@article{a14057e87474457cbf0a2df7782863e9,

title = "Effect of Brij-78 on systemic delivery of insulin from an ocular device",

abstract = "An ocular insert is developed for the controlled systemic delivery of insulin. Commercially available Gelfoam absorbable gelatin sponge, USP, is used in the fabrication of the ocular insert in the form of a matrix system. Two eyedrop formulations and 13 eye device formulations were evaluated. The efficacy of insulin ocular delivery was quantitated by monitoring the changes in its pharmacological response (i.e., blood glucose lowering). The in vivo results from devices containing 0.5 or 1.0 mg of insulin with 20 μg of p.- 2. ether (Brij-78) give a substantial improvement in insulin activity and a significant prolongation in its duration compared with the eyedrops. In addition, the mean blood glucose concentration returns to nearly normal levels within 60 rain after the removal of the device. Overall, the application of the Gelfoam device makes it feasible to obtain a prolonged systemic delivery of insulin within the desired therapeutic levels without the risk of hypoglycemia.",

author = "Lee, {Yung Chi} and Pahala Simamora and Yalkowsky, {Samuel H.}",

note = "Funding Information: We thank the Pharmacia & Upjohn Company (Kalamazoo, MI) for providing samples of Gelfoam sponge and the Lifescan Company (Mountain View, CA) for supplying the ONE TOUCH BASIC blood glucose monitoring system. This work was financially supported by the National Cancer Institute (NCI-CM-27757).",

year = "1997",

month = apr,

doi = "10.1021/js960423s",

language = "English (US)",

volume = "86",

pages = "430--433",

journal = "Journal of pharmaceutical sciences",

issn = "0022-3549",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Effect of Brij-78 on systemic delivery of insulin from an ocular device

AU - Lee, Yung Chi

AU - Simamora, Pahala

AU - Yalkowsky, Samuel H.

N1 - Funding Information: We thank the Pharmacia & Upjohn Company (Kalamazoo, MI) for providing samples of Gelfoam sponge and the Lifescan Company (Mountain View, CA) for supplying the ONE TOUCH BASIC blood glucose monitoring system. This work was financially supported by the National Cancer Institute (NCI-CM-27757).

PY - 1997/4

Y1 - 1997/4

N2 - An ocular insert is developed for the controlled systemic delivery of insulin. Commercially available Gelfoam absorbable gelatin sponge, USP, is used in the fabrication of the ocular insert in the form of a matrix system. Two eyedrop formulations and 13 eye device formulations were evaluated. The efficacy of insulin ocular delivery was quantitated by monitoring the changes in its pharmacological response (i.e., blood glucose lowering). The in vivo results from devices containing 0.5 or 1.0 mg of insulin with 20 μg of p.- 2. ether (Brij-78) give a substantial improvement in insulin activity and a significant prolongation in its duration compared with the eyedrops. In addition, the mean blood glucose concentration returns to nearly normal levels within 60 rain after the removal of the device. Overall, the application of the Gelfoam device makes it feasible to obtain a prolonged systemic delivery of insulin within the desired therapeutic levels without the risk of hypoglycemia.

AB - An ocular insert is developed for the controlled systemic delivery of insulin. Commercially available Gelfoam absorbable gelatin sponge, USP, is used in the fabrication of the ocular insert in the form of a matrix system. Two eyedrop formulations and 13 eye device formulations were evaluated. The efficacy of insulin ocular delivery was quantitated by monitoring the changes in its pharmacological response (i.e., blood glucose lowering). The in vivo results from devices containing 0.5 or 1.0 mg of insulin with 20 μg of p.- 2. ether (Brij-78) give a substantial improvement in insulin activity and a significant prolongation in its duration compared with the eyedrops. In addition, the mean blood glucose concentration returns to nearly normal levels within 60 rain after the removal of the device. Overall, the application of the Gelfoam device makes it feasible to obtain a prolonged systemic delivery of insulin within the desired therapeutic levels without the risk of hypoglycemia.

UR - http://www.scopus.com/inward/record.url?scp=0030910345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030910345&partnerID=8YFLogxK

U2 - 10.1021/js960423s

DO - 10.1021/js960423s

M3 - Article

C2 - 9109043

SN - 0022-3549

VL - 86

SP - 430

EP - 433

JO - Journal of pharmaceutical sciences

JF - Journal of pharmaceutical sciences

IS - 4

ER -

Effect of Brij-78 on systemic delivery of insulin from an ocular device

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this